ES2095001T3 - Una composicion terapeutica administrable oralmente y su metodo de obtencion. - Google Patents
Una composicion terapeutica administrable oralmente y su metodo de obtencion.Info
- Publication number
- ES2095001T3 ES2095001T3 ES93300005T ES93300005T ES2095001T3 ES 2095001 T3 ES2095001 T3 ES 2095001T3 ES 93300005 T ES93300005 T ES 93300005T ES 93300005 T ES93300005 T ES 93300005T ES 2095001 T3 ES2095001 T3 ES 2095001T3
- Authority
- ES
- Spain
- Prior art keywords
- protein
- orally
- therapeutic protein
- obtaining
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 239000013566 allergen Substances 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 210000004051 gastric juice Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000003094 microcapsule Substances 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE PRESENTA UNA PROTEINA TERAPEUTICA ADMINISTRABLE ORALMENTE COMBINANDO LA PROTEINA TERAPEUTICA CON UN AGENTE ESTABILIZADOR EN UNA SOLUCION ACUOSA. LA SOLUCION SE REVISTE SIN PARES MICROENCAPSULADOS CON UNA COMPOSICION DE REVESTIMIENTO ENTERICA HIDROEMULGENTE. LAS MICROCAPSULAS SE ADMINISTRAN ORALMENTE. LOS REVESTIMIENTOS PROTEGEN LA PROTEINA CUANDO PASA A TRAVES DEL ESTOMAGO. AL ALCANZAR LOS INTESTINOS DELGADOS, EL PH BASICO DE LOS JUGOS GASTRICOS DISUELVEN EL REVESTIMIENTO, PERMITIENDO QUE LA PROTEINA SEA LIBERADA Y QUE INDUZCA LA RESPUESTA INMUNE ESPECIFICA DE ANTIGENO QUE TIENE LA ESPECIFICIDAD DE LA MOLECULA NATIVA. EL AGENTE DE ESTABILIZACION PROTEGE LA PROTEINA TERAPEUTICA DE LA DESNATURALIZACION DURANTE EL PROCESO DE ENCAPSULACION. ADEMAS AL SER INMUNOGENICO, CUANDO SE ADMINISTRA ORALMENTE, EL ALERGENO ENCAPSULADO TIENE UN EFECTO TERAPEUTICO EN EL TRATAMIENTO DE ALERGIA HUMANA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99493292A | 1992-12-22 | 1992-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2095001T3 true ES2095001T3 (es) | 1997-02-01 |
ES2095001T5 ES2095001T5 (es) | 2001-03-16 |
Family
ID=25541237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES93300005T Expired - Lifetime ES2095001T5 (es) | 1992-12-22 | 1993-01-04 | Una composicion terapeutica administrable oralmente y su metodo de obtencion. |
Country Status (12)
Country | Link |
---|---|
US (1) | US5591433A (es) |
EP (1) | EP0603992B2 (es) |
JP (1) | JPH0710771A (es) |
AT (1) | ATE143803T1 (es) |
AU (1) | AU664222B2 (es) |
CA (1) | CA2086631C (es) |
DE (1) | DE69305313T3 (es) |
DK (1) | DK0603992T4 (es) |
ES (1) | ES2095001T5 (es) |
GR (2) | GR3022090T3 (es) |
NZ (1) | NZ245618A (es) |
SG (1) | SG52402A1 (es) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2109362T3 (es) * | 1991-06-21 | 1998-01-16 | Univ Cincinnati | Unas proteinas administrables oralmente y metodo para hacerlas. |
US6613332B1 (en) | 1991-06-21 | 2003-09-02 | The University Of Cincinnati | Oral administration of therapeutic proteins |
US6083503A (en) * | 1991-08-28 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection |
BR9507452A (pt) * | 1994-04-08 | 1997-08-05 | Brigham & Womens Hospital | Composição farmacêutica uso de um polipeptídeo não-interferon uso de uma quantidade de um antígeno padronizado e uma quantidade de um polipeptídeo não-interferon e produto contendo (1) uma quantidade de um antígeno padronizado e (11) uma quantidade de um polipeptídeo não-interferon |
US20030202980A1 (en) * | 1995-12-29 | 2003-10-30 | Caplan Michael J. | Methods and reagents for decreasing clinical reaction to allergy |
US5980948A (en) * | 1996-08-16 | 1999-11-09 | Osteotech, Inc. | Polyetherester copolymers as drug delivery matrices |
WO1998007443A1 (fr) * | 1996-08-20 | 1998-02-26 | Freund Industrial Co., Ltd. | Microspheres contenant des immunogenes, procede de fabrication et procede permettant d'immuniser des animaux a l'aide de ces microspheres |
WO1998009645A1 (fr) * | 1996-09-04 | 1998-03-12 | Dott Research Laboratory | Compositions medicamenteuses contenant des peptides, destinees a l'administration orale |
US8828432B2 (en) | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
US6559158B1 (en) | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
US7879977B2 (en) | 1998-01-31 | 2011-02-01 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
CA2319437C (en) * | 1998-01-31 | 2009-06-16 | University Of Arkansas | Methods and reagents for decreasing allergic reactions |
US6328967B1 (en) * | 1998-03-12 | 2001-12-11 | Allergenics, Inc. | Delivery system to modulate immune response |
US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
PL193929B1 (pl) | 1998-03-23 | 2007-04-30 | Gen Mills Inc | Jadalny produkt na bazie skrobi, kompozycja odżywcza oraz sposób wytwarzania jadalnego produktu |
SE9801288D0 (sv) * | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
GB9818591D0 (en) * | 1998-08-27 | 1998-10-21 | Danbiosyst Uk | Pharmaceutical composition |
WO2000054797A2 (en) | 1999-03-17 | 2000-09-21 | Novartis Ag | Pharmaceutical compositions comprising tgf-beta |
US6500463B1 (en) | 1999-10-01 | 2002-12-31 | General Mills, Inc. | Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
US20010026800A1 (en) * | 2000-01-07 | 2001-10-04 | Michael Jacob G. | Selective activation of a TH1 or TH2 lymphocyte regulated immune response |
US20050063994A1 (en) * | 2000-04-06 | 2005-03-24 | Caplan Michael J. | Methods and reagents for decreasing clinical reaction to allergy |
AU1951001A (en) * | 2000-04-06 | 2001-09-17 | Panacea Pharm Llc | Microbial delivery system |
US8246945B2 (en) * | 2000-04-06 | 2012-08-21 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
US6468568B1 (en) | 2000-06-16 | 2002-10-22 | General Mills, Inc. | Oligosaccharide encapsulated mineral and vitamin ingredients |
US6436453B1 (en) | 2000-06-16 | 2002-08-20 | General Mills, Inc. | Production of oil encapsulated minerals and vitamins in a glassy matrix |
US6558718B1 (en) | 2000-06-19 | 2003-05-06 | General Mills, Inc. | Nutrient clusters for food products and methods of preparation |
CN1268641C (zh) | 2000-11-10 | 2006-08-09 | 普罗蒂奥制药公司 | 载脂蛋白类似物 |
WO2002098422A1 (en) * | 2001-06-05 | 2002-12-12 | University Of Chicago | Use of methylnaltrexone to treat immune suppression |
KR20040047915A (ko) * | 2001-10-15 | 2004-06-05 | 룀 게엠베하 운트 콤파니 카게 | 활성제로서 펩타이드 또는 단백질을 함유하는 생약 형태를제조하기 위한 공중합체의 용도 |
KR100469943B1 (ko) * | 2002-03-20 | 2005-02-02 | 삼성정밀화학 주식회사 | 장용성 코팅제로 사용되는 아크릴 공중합체의 제조 방법 |
US20040043070A1 (en) * | 2002-05-14 | 2004-03-04 | Ayres James W. | Hot melt coating by direct blending and coated substrates |
US7431986B2 (en) | 2002-07-24 | 2008-10-07 | General Mills, Inc. | Encapsulation of sensitive components using pre-emulsification |
CA2521369A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
EP1638607A1 (en) * | 2003-04-08 | 2006-03-29 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
PL2368553T3 (pl) * | 2003-04-08 | 2015-05-29 | Progenics Pharm Inc | Preparaty farmaceutyczne zawierające metylonaltrekson |
US20070141071A1 (en) * | 2003-05-14 | 2007-06-21 | Oregon State University | Hot melt coating by direct blending and coated substrates |
US20060029590A1 (en) * | 2004-06-10 | 2006-02-09 | Christopher Thanos | Administration of neutral endopeptidase to treat inflammatory bowel disease |
JP2008502605A (ja) * | 2004-06-16 | 2008-01-31 | スマート ドラッグ システムズ インコーポレイティド | 徐放性ワクチン組成物 |
EP1845989A1 (en) * | 2005-01-20 | 2007-10-24 | Progenics Pharmaceuticals, Inc. | Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction |
MX2007010833A (es) * | 2005-03-07 | 2009-02-17 | Univ Chicago | Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales. |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
AR057035A1 (es) * | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
US20080194611A1 (en) * | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
CA2624503A1 (en) * | 2005-10-04 | 2007-04-12 | Alk-Abello A/S | Solid vaccine formulation |
US7803413B2 (en) | 2005-10-31 | 2010-09-28 | General Mills Ip Holdings Ii, Llc. | Encapsulation of readily oxidizable components |
WO2007112747A1 (en) * | 2006-03-31 | 2007-10-11 | Curalogic A/S | Immunogen combinations |
TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
JP2010522756A (ja) | 2007-03-29 | 2010-07-08 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | 結晶形およびその使用 |
AU2008233129B2 (en) * | 2007-03-29 | 2014-03-20 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
ES2540551T3 (es) * | 2007-03-29 | 2015-07-10 | Wyeth Llc | Antagonistas de receptores opioides periféricos y usos de los mismos |
CN101959892B (zh) * | 2008-02-06 | 2014-01-08 | 普罗热尼奇制药公司 | (r),(r)-2,2’-二-甲基纳曲酮的制备和用途 |
JP5647098B2 (ja) | 2008-03-21 | 2014-12-24 | ザ ユニヴァーシティー オヴ シカゴ | オピオイド拮抗薬とmTOR阻害薬を用いた治療 |
US8703152B2 (en) | 2008-06-03 | 2014-04-22 | University Of Rochester | Methods of treating inflammatory intestinal disease and managing symptoms thereof |
WO2010002576A1 (en) | 2008-07-01 | 2010-01-07 | University Of Chicago | Particles containing an opioid receptor antagonist and methods of use |
JP2010077057A (ja) * | 2008-09-25 | 2010-04-08 | Kagoshima Univ | 抗食物アレルギーワクチン |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
JP5931449B2 (ja) * | 2012-01-11 | 2016-06-08 | 日東電工株式会社 | 医薬組成物及びその製造方法 |
US10940170B2 (en) | 2014-07-07 | 2021-03-09 | University Of Massachusetts | Anthelmintic probiotic compositions and methods |
EP3718404A1 (en) | 2014-10-17 | 2020-10-07 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progession |
US11484568B2 (en) | 2016-01-15 | 2022-11-01 | University Of Massachusetts | Anthelmintic compositions and methods |
US11844815B2 (en) | 2017-05-23 | 2023-12-19 | University Of Massachusetts | Purified anthelmintic compositions and related methods |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2020257017A1 (en) | 2019-06-18 | 2020-12-24 | Progenity, Inc. | Ingestible device with component capable of residing in the gastrointestinal tract |
US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE621398A (es) * | 1900-01-01 | |||
US3143473A (en) * | 1961-08-16 | 1964-08-04 | Behringwerke Ag | Stable, solid, oral live antipoliomyelitis vaccine compositions and process for preparing them |
US3458621A (en) * | 1966-08-31 | 1969-07-29 | American Home Prod | Tablet dosage-form for the immunization of the intestinal tract with live virus preparations |
US3909444A (en) * | 1971-08-05 | 1975-09-30 | Ncr Co | Microcapsule |
US3823228A (en) * | 1971-09-29 | 1974-07-09 | Univ Illinois | Tge virus vaccine |
US3860490A (en) * | 1972-02-11 | 1975-01-14 | Nat Patent Dev Corp | Process of subjecting a microorganism susceptible material to a microorganism |
US3767790A (en) * | 1972-02-11 | 1973-10-23 | Nat Patent Dev Corp | Microorganisms |
US4016254A (en) * | 1972-05-19 | 1977-04-05 | Beecham Group Limited | Pharmaceutical formulations |
JPS517116A (en) * | 1974-06-11 | 1976-01-21 | Shinetsu Chemical Co | Choyoseihifukuyakuzaino seizohoho |
US4269764A (en) * | 1979-08-02 | 1981-05-26 | Roy Patterson | Preparation for treatment of allergic patients sensitive to ragweed pollen |
US4469677A (en) * | 1980-02-19 | 1984-09-04 | Michael J Gabriel | Polypeptide active immunosuppressant fraction |
JPS5855125B2 (ja) * | 1980-03-10 | 1983-12-08 | 信越化学工業株式会社 | 固形薬剤用腸溶性コ−テイング剤組成物 |
JPS56142211A (en) * | 1980-04-09 | 1981-11-06 | Riken Vitamin Co Ltd | Production of enteric preparation |
US4348384A (en) * | 1980-10-17 | 1982-09-07 | Dainippon Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX |
US4507276A (en) * | 1982-08-20 | 1985-03-26 | Bristol-Myers Company | Analgesic capsule |
SE8303401D0 (sv) * | 1983-06-15 | 1983-06-15 | Pharmacia Ab | Beredning och dess anvendning |
GB8321178D0 (en) * | 1983-08-05 | 1983-09-07 | Beecham Group Plc | Compositions |
US4704295A (en) * | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
US4794000A (en) * | 1987-01-08 | 1988-12-27 | Synthetic Blood Corporation | Coacervate-based oral delivery system for medically useful compositions |
DE3431861A1 (de) * | 1984-08-30 | 1986-03-13 | Troponwerke GmbH & Co KG, 5000 Köln | Pellet-zubereitung |
ZA858044B (en) * | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
EP0192321A3 (en) * | 1985-01-19 | 1987-09-02 | Beecham Group Plc | Enteric coated allergen pharmaceutical composition |
CH663900A5 (de) * | 1985-05-06 | 1988-01-29 | Cernitin Sa | Pharmazeutisches praeparat zur prophylaktischen behandlung von allergien und verfahren zur herstellung dieses praeparates. |
IL78775A (en) * | 1985-05-15 | 1992-06-21 | Biotech Australia Pty Ltd | Oral vaccines |
GB8519310D0 (en) * | 1985-07-31 | 1985-09-04 | Zyma Sa | Granular active substances |
US4820627A (en) * | 1986-03-24 | 1989-04-11 | Em Diagnostic Systems, Inc. | Method of preparing particles suitable for tabletting into diagnostic reagents |
JPH0759496B2 (ja) * | 1986-03-25 | 1995-06-28 | ロ−ト製薬株式会社 | 歯周病治療剤 |
US5075109A (en) * | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
FR2609895B1 (fr) * | 1987-01-28 | 1991-06-28 | Bruttmann Georges | Nouvelles formes galeniques d'allergenes pour administration par voie per- et sub-linguale |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
JPS6417A (en) * | 1987-02-20 | 1989-01-05 | Shikoku Chem Corp | Chemotherapeutic agent composition |
US4874613A (en) * | 1987-03-06 | 1989-10-17 | Baker Cummins Pharmaceuticals, Inc. | Taste concealing pharmaceutical dosage unit |
US4946945A (en) * | 1987-06-23 | 1990-08-07 | Allergy Immuno Technologies, Inc. | Immunotherapy agents for treatment of IgE mediated allergies |
US5116612A (en) * | 1987-06-23 | 1992-05-26 | Allergy Immuno Technologies, Inc. | Immunotherapy agents for treatment of IgE mediated allergies |
US5049390A (en) * | 1987-09-02 | 1991-09-17 | Allergy Immuno Technologies, Inc. | Liposome containing immunotherapy agents for treating IgE mediated allergies |
IL87710A (en) * | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
US5236713A (en) * | 1987-10-21 | 1993-08-17 | Teikoku Seiyaku Kabushiki Kaisha | Preparation for intermittently releasing active agent applicable to oral cavity |
GB8826116D0 (en) * | 1988-11-08 | 1988-12-14 | Danbiosyst Ltd | Adhesive drug delivery composition |
WO1990011070A1 (en) * | 1989-03-17 | 1990-10-04 | Pitman-Moore, Inc. | Controlled release delivery device for macromolecular proteins |
US5047258A (en) * | 1989-07-14 | 1991-09-10 | Sterling Drug Inc. | Aqueous spray-coating process |
US5032405A (en) * | 1989-09-27 | 1991-07-16 | Warner-Lambert Company | Oral pharmaceutical composition for acid sensitive proteinaceous agents |
AU7908791A (en) * | 1990-05-08 | 1991-11-27 | Liposome Technology, Inc. | Direct spray-dried drug/lipid powder composition |
US5149543A (en) * | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
JP2635444B2 (ja) * | 1990-10-15 | 1997-07-30 | オートイミューン インク | 自己抗体の経口投与による自己免疫性疾患の治療 |
JPH04230625A (ja) * | 1990-12-27 | 1992-08-19 | Standard Chem & Pharmaceut Corp Ltd | 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法 |
ES2109362T3 (es) † | 1991-06-21 | 1998-01-16 | Univ Cincinnati | Unas proteinas administrables oralmente y metodo para hacerlas. |
US5160742A (en) * | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
-
1993
- 1993-01-04 ES ES93300005T patent/ES2095001T5/es not_active Expired - Lifetime
- 1993-01-04 AT AT93300005T patent/ATE143803T1/de not_active IP Right Cessation
- 1993-01-04 DK DK93300005T patent/DK0603992T4/da active
- 1993-01-04 DE DE1993605313 patent/DE69305313T3/de not_active Expired - Lifetime
- 1993-01-04 SG SG1996004016A patent/SG52402A1/en unknown
- 1993-01-04 CA CA 2086631 patent/CA2086631C/en not_active Expired - Lifetime
- 1993-01-04 EP EP19930300005 patent/EP0603992B2/en not_active Expired - Lifetime
- 1993-01-05 AU AU31045/93A patent/AU664222B2/en not_active Ceased
- 1993-01-06 JP JP3107493A patent/JPH0710771A/ja active Pending
- 1993-01-06 NZ NZ245618A patent/NZ245618A/en not_active IP Right Cessation
-
1995
- 1995-01-20 US US08/405,604 patent/US5591433A/en not_active Expired - Lifetime
-
1996
- 1996-12-18 GR GR960403537T patent/GR3022090T3/el unknown
-
2001
- 2001-02-22 GR GR20010400286T patent/GR3035452T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US5591433A (en) | 1997-01-07 |
DK0603992T3 (da) | 1997-03-24 |
NZ245618A (en) | 1994-10-26 |
GR3035452T3 (en) | 2001-05-31 |
AU3104593A (en) | 1994-07-07 |
ATE143803T1 (de) | 1996-10-15 |
EP0603992B2 (en) | 2000-12-06 |
EP0603992B1 (en) | 1996-10-09 |
CA2086631A1 (en) | 1994-06-23 |
AU664222B2 (en) | 1995-11-09 |
SG52402A1 (en) | 1998-09-28 |
JPH0710771A (ja) | 1995-01-13 |
EP0603992A1 (en) | 1994-06-29 |
CA2086631C (en) | 1998-10-06 |
ES2095001T5 (es) | 2001-03-16 |
DE69305313D1 (de) | 1996-11-14 |
GR3022090T3 (en) | 1997-03-31 |
DE69305313T3 (de) | 2001-06-21 |
DE69305313T2 (de) | 1997-02-20 |
DK0603992T4 (da) | 2001-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2095001T3 (es) | Una composicion terapeutica administrable oralmente y su metodo de obtencion. | |
ES2109362T3 (es) | Unas proteinas administrables oralmente y metodo para hacerlas. | |
MX9304346A (es) | Composicion de vacuna oral para especies rumiantes y metodo para su produccion. | |
NO156275C (no) | Fremgangsmaate for fremstilling av kapsler inneholdende et toert, pulverformet allergenpreparat. | |
RU95119625A (ru) | Способ лечения полипоза желудочно-кишечного тракта | |
NO900358D0 (no) | Fremgangsmaate og innretning for behandling av faststoff-gass-blandinger som skal pumpes. | |
GR3004069T3 (es) | ||
US3133860A (en) | Method of treating alimentary canal ulcers with sagebrush oil | |
DE69906964T2 (de) | Diaganostische methode und diagnostische mittel die verwendet werden besagte methode auszuführen | |
RU94028204A (ru) | Препарат "уберсан" для лечения мастита у сельскохозяйственных животных | |
CRABB et al. | The typing of Escherichia coli by bacteriophage: its application in the study of the E. coli population of the intestinal tract of healthy calves and of calves suffering from white scours | |
RU93000004A (ru) | Вещество для лечения подкожной фибрасаркомы и способ его получения | |
SU404478A1 (ru) | Эмульгатор | |
Livingston et al. | Peptic ulcer disease | |
RU94003799A (ru) | Способ лечения псороптозов животных | |
JPS5771374A (en) | Garlic seasoning | |
MURINE | PSEUDOMONAS AEKÜ6IN0SA TOXOID | |
TH40758A (th) | ยาบำรุงกำลังเพศชาย กระตุ้นสมรรถภาพทางเพศแก้กระษัย ขับปัสสาวะ | |
SE9003096D0 (sv) | Device for administering a physiologically active substance to the gastro-intestinal tract | |
WAMPLER | Everything in the World | |
RU96123823A (ru) | Гомеопатическое лекарственное средство для стимуляции эрекции "эректин-arn" | |
RU94033867A (ru) | Способ стимуляции apud-системы | |
TH36118B (th) | กรรมวิธีใหม่สำหรับเตรียมเพพไทด์ที่ถูกไลโอฟิไลซ์ | |
RU93056259A (ru) | Средство для лечения диспепсии телят | |
RU93029906A (ru) | Способ лечения нарушений дуоденальной проходимости при язвенной болезни и постгастрорезекционных синдромах |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 603992 Country of ref document: ES |